GV, Sanofi drive British biotech OMass to $100M series B, fueling work on undruggable targets

Published

April 28, 2022

GV, Sanofi drive British biotech OMass to $100M series B, fueling work on undruggable targets

GV, Northpond Ventures and Sanofi Ventures have joined forces to pump $100 million into OMass Therapeutics, teeing the British biotech up to advance candidates against hard-to-hit targets toward the clinic…

MORERelated News
Ros Deegan: Always up for a new challenge: How Ros carved out a path to lead her own company
Always up for a new challenge, Ros describes the many twists and turns her career has taken over the years....
Lab crunch: British science has nowhere to go
OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm...
Native mass spectrometry: Drug discovery’s new kid on the block
Current drug discovery methods have limited success against certain drug targets and better approaches are needed. Professor Dame Carol Robinson’s...